Single Arm, Neoadjuvant, Phase II Trial of Pertuzumab and Trastuzumab Administered Concomitantly With Weekly Paclitaxel and FEC for Clinical Stage I-II HER2-Positive Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Jan 2018
At a glance
- Drugs Pertuzumab (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil; Paclitaxel; Trastuzumab
- Indications Breast cancer
- Focus Therapeutic Use
- 10 Jan 2018 Planned End Date changed from 1 Jun 2017 to 1 Dec 2018.
- 10 Jan 2018 Planned primary completion date changed from 1 Dec 2016 to 1 Jul 2018.
- 10 Jun 2017 Biomarkers information updated